Healthy Participants
Conditions
Keywords
Fibroblast Activation Protein inhibitor, Advanced hepatic fibrosis, Chronic liver disease
Brief summary
The purpose of this study is to assess the pharmacokinetics (PK) of AZD2389 when administered alone and in combination with itraconazole in healthy participants.
Detailed description
This study will be an open-label, fixed sequence, Drug-Drug Interaction (DDI) study consisting of 3 periods. The study will comprise: * A screening period of maximum 28 days * Period 1 * Period 2 * Period 3 * A Follow-up Visit 7 to 14 days after the last PK sample has been collected.
Interventions
DRUGAZD2389
AZD2389 is administered orally
DRUGItraconazole
Itraconazole is administered orally
Sponsors
Parexel
AstraZeneca
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit. * Females of non-childbearing potential must be postmenopausal for at least 12 months or have documentation of irreversible surgical sterilization. * Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods. * Have a Body Mass Index (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50 kg.
Exclusion criteria
* History of any clinically important disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study. * History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention. * Abnormal laboratory values, clinically important abnormalities or abnormal vital signs * Any positive result on screening for serum Hepatitis B surface antigen/antibody, Hepatitis C, or Human Immunodeficiency Virus. * Current smokers (within 3 months prior to screening visit) or history of alcohol and drug abuse * History of severe allergy or hypersensitivity * Excessive intake of caffeine-containing drinks or food * Use of drugs with enzyme inducing properties or use of any prescribed or nonprescribed medication including antacids, analgesics
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum observed drug concentration (Cmax) of AZD2389 | Day 1 to Day 8 | To assess the effect of itraconazole on the Cmax of AZD2389. |
| Area under concentration-timecurve from time zero to infinity (AUCinf) of AZD2389 | Day 1 to Day 8 | To assess the effect of itraconazole on the AUCinf of AZD2389. |
| Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of AZD2389 | Day 1 to Day 8 | To assess the effect of itraconazole on the AUClast of AZD2389. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to reach maximum observed concentration (tmax) of AZD2389 | Day 1 to Day 8 | To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole. |
| Ratio of Test treatment (AZD2389 + itraconazole) to Reference (AZD2389) based on Cmax (RCmax) of AZD2389 | Day 1 to Day 8 | To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole. |
| Ratio of Test treatment (AZD2389 + itraconazole) to Reference (AZD2389) based on AUClast (RAUClast) of AZD2389 | Day 1 to Day 8 | To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole. |
| Ratio of Test treatment (AZD2389 + itraconazole) to Reference (AZD2389) based on AUCinf (RAUCinf) of AZD2389 | Day 1 to Day 8 | To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole. |
| Apparent total body clearance (CL/F) of AZD2389 | Day 1 to Day 8 | To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole |
| Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 (Ae(t1-t2)) of AZD2389 | Day 1 to Day 8 | To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole. |
| Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 (fe(t1-t2)) of AZD2389 | Day 1 to Day 8 | To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole. |
| Percent change from baseline in fibroblast activation protein (FAP) inhibition | Day 1 to Day 8 | To evaluate the pharmacodynamics (PD) of AZD2389 by assessment of inhibition of FAP activity in plasma after single oral dose of AZD2389 alone or in combination with itraconazole. |
| Number of participants with Adverse Events (AEs) | From Screening (Day -29 to Day -2) up to 8 weeks | To assess the safety and tolerability of a single oral dose of AZD2389 alone or in combination with itraconazole in healthy participants. |
| Renal Clearance (CLR) of AZD2389 | Day 1 to Day 8 | To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole. |
| Apparent volume of distribution based on the terminal phase (Vz/F) of AZD2389 | Day 1 to Day 8 | To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole |
| Terminal elimination half-life (t1/2λz) of AZD2389 | Day 1 to Day 8 | To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole. |
Countries
United States
Outcome results
None listed